PBLS Parabilis Medicines, Inc.
Price Chart
Executive Summary
Parabilis Medicines priced its upsized IPO of 33.5M shares at $20.00/share, expecting gross proceeds of $670M, plus a concurrent private placement to Regeneron for ~$75M. The IPO is a major capital event for a clinical-stage biotech, providing substantial cash runway to advance its Helicon platform.
Key Financial Metrics
Actionable Insight
The IPO provides a massive cash infusion for a clinical-stage biotech, reducing near-term dilution risk and funding pipeline development. Watch for the Regeneron partnership details and any early clinical data readouts that could drive further upside.
Key Facts
- Upsized IPO of 33,500,000 shares at $20.00 per share, expected gross proceeds of $670 million.
- Concurrent private placement of 4,166,666 shares at $18.00 per share to Regeneron Pharmaceuticals for ~$75 million.
- Underwriters have a 30-day option to purchase an additional 5,025,000 shares.
- Trading on Nasdaq under ticker PBLS expected to begin June 10, 2026; closing expected June 11, 2026.
- Lead underwriters: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities.
Financial Impact
Total gross proceeds of $670M from IPO plus ~$75M from private placement = ~$745M in new capital.
Risk Factors
- Clinical-stage company with no approved products; pipeline risk is high.
- Dilution from the IPO and potential full exercise of the underwriters' option (additional 5M shares).
- Forward-looking statements subject to customary closing conditions and market volatility.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $30.30 awaiting T+20 | awaiting T+20 | — | $27.26 (−10.03%) |
|
Jun 10, 2026
4d ago
|
424B4
| $32.16 awaiting T+20 | awaiting T+20 | — | $27.26 (−15.24%) |
|
Jun 10, 2026
5d ago
|
EFFECT
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access